Cargando…

SPG15: A Rare Correlation with Atypical Juvenile Parkinsonism Responsive to Levodopa

Detalles Bibliográficos
Autores principales:	Araujo, Filipe Miranda Milagres, Junior, Wilson Marques, Tomaselli, Pedro José, Pimentel, Ângela V., Macruz Brito, Manuelina C., Tumas, Vitor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533969/ https://www.ncbi.nlm.nih.gov/pubmed/33033739 http://dx.doi.org/10.1002/mdc3.13027

Ejemplares similares

Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study
por: Santos-Lobato, Bruno Lopes, et al.
Publicado: (2023)

Direct and indirect assessment of functional abilities in patients with Parkinson’s disease transitioning to dementia
por: de Oliveira, Gisele Saraiva Reis, et al.
Publicado: (2020)

The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia
por: Novaretti, Nathália, et al.
Publicado: (2019)

An integrated modelling methodology for estimating global incidence and prevalence of hereditary spastic paraplegia subtypes SPG4, SPG7, SPG11, and SPG15
por: Vander Stichele, Geert, et al.
Publicado: (2022)

Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11
por: Renvoisé, Benoît, et al.
Publicado: (2014)

Side effects induced by the acute levodopa challenge in Parkinson’s Disease and atypical parkinsonisms
por: Vasta, Rosario, et al.
Publicado: (2017)

Interaction between AP-5 and the hereditary spastic paraplegia proteins SPG11 and SPG15
por: Hirst, Jennifer, et al.
Publicado: (2013)

Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease
por: Tumas, Vitor, et al.
Publicado: (2016)

Rag GTPases and phosphatidylinositol 3-phosphate mediate recruitment of the AP-5/SPG11/SPG15 complex
por: Hirst, Jennifer, et al.
Publicado: (2021)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease.
por: Gangemi, Sebastiano, et al.
Publicado: (2003)

Turkish families with juvenile motor neuron disease broaden the phenotypic spectrum of SPG11
por: Iskender, Ceren, et al.
Publicado: (2015)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Alimentation SPG Test
por: Guillet, J
Publicado: (1993)

Rescue of lysosomal function as therapeutic strategy for SPG15 hereditary spastic paraplegia
por: Vantaggiato, Chiara, et al.
Publicado: (2022)

Bipolar disorder, a precursor of Parkinson's disease?
por: Novaretti, Tânia M.S., et al.
Publicado: (2016)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Successful Utilization of Levodopa in HIV-Induced Parkinsonism
por: Almajali, Mohammad, et al.
Publicado: (2020)

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
por: Beckers, Milan, et al.
Publicado: (2022)

Determinants of Levodopa Responsiveness in Patients with Vascular Parkinsonism
por: Goyal, Sheetal, et al.
Publicado: (2022)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
por: Carvalho, Miguel M., et al.
Publicado: (2017)

SPG11 Presenting with Tremor
por: Schneider, Susanne A., et al.
Publicado: (2012)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Levodopa-Responsive Early-Onset Parkinsonism in Down Syndrome
por: Palat, Padmini, et al.
Publicado: (2018)

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
por: Mueller, Karsten, et al.
Publicado: (2018)

Impact of Levodopa in Lung Functions in Patients with Parkinson Disease
por: Tandon, Medha, et al.
Publicado: (2020)

Biphasic Levodopa-Induced Freezing of Gait in Parkinson’s Disease
por: Nonnekes, Jorik, et al.
Publicado: (2020)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Impact of Levodopa in Lung Functions in Patients with Parkinson’s Disease
por: Al-Mendalawi, Mahmood D.
Publicado: (2021)

Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
por: Alabrahim, Obaydah Abd Alkader, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i2tlnil64b3v1dhffdki17ltgj